Enacts the manufacturer disclosure and transparency act
Summary
Enacts the manufacturer disclosure and transparency act requiring prescription drug manufacturers to notify the attorney general of arrangements between pharmaceutical manufacturers resulting in the delay of the introduction of generic medications.
Bill status
in committee
1 of 4 stages cleared
Introduction
Jan 2023
Committee Review
Floor Vote
Governor
Introduced Jan 11, 2023
Last action Jan 3, 2024
Floor votes
How they voted
No floor votes recorded yet.
Full legislative history
Actions timeline
Total actions
2
Key actions
0
Committee
2
Jan 3, 2024
Committee
REFERRED TO CONSUMER AFFAIRS AND PROTECTION
lower
Jan 11, 2023
Committee
REFERRED TO CONSUMER AFFAIRS AND PROTECTION
lower
1 primary · 25 co-sponsors
Sponsors
Role
Legislator
Party
State
District
P
Emily Gallagher
DDemocratic
Co
Aileen Gunther
DDemocratic
Co
Al Stirpe
DDemocratic
Co
Angelo Santabarbara
DDemocratic
Co
Donna Lupardo
DDemocratic
Co
Gina Sillitti
DDemocratic/Working Families
Co
Harvey Epstein
DDemocratic
Co
Inez Dickens
DDemocratic
Co
Jessica González-Rojas
DDemocratic/Working Families
Co
Jo Anne Simon
DDemocratic
Co
Karines Reyes
DDemocratic
Ask Maddy
·
AI policy assistant
Ask Maddy about A 895
Scope: NY
Hi! I can help you understand A 895. What would you like to know?
Try one of these
i
Maddy answers using official bill text and legislative records. Always verify before sharing.
Sources cited inline